Search
Tianchen Biopharma Hastens to Hong Kong Stock Exchange: Pioneering "Allergy + Autoimmune" Sector, Core Product Anticipated to Outperform Omalizumab
2025-08-27 /
Read about 0 minute
Author：小编
On August 21, 2025, Tianchen Biopharma (Suzhou) Co., Ltd. filed a prospectus with the Hong Kong Stock Exchange, aiming for a listing on the main board. The company is dedicated to the research and development of treatments for allergic and autoimmune disorders. Its flagship product, LP-003, stands as the most advanced candidate in clinical development among the next generation of anti-IgE biologics worldwide.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
